论文部分内容阅读
目的探讨分析培美曲塞联合奈达铂治疗晚期肺腺癌的临床观察。方法选取襄城县人民医院2013年7月至2014年7月收治的94例晚期肺腺癌患者,将其分为观察组(47例)和对照组(47例),给予观察组患者行培美曲塞联合奈达铂治疗,给予对照组患者吉西他滨联合奈达铂治疗,观察两组患者治疗效果、不良反应、生存质量改善情况等指标。结果经治疗,观察组总有效率为91.48%,对照组为72.34%,两组对比差异有统计学意义(P<0.05)。观察组Ⅲ度以上白细胞减少发生率低于对照组,两组对比差异有统计学意义(P<0.05)。但其他不良反应发生率相比差异未见统计学意义(P>0.05),患者化疗常见不良反应有恶心呕吐、脱发、骨髓抑制、肝肾功能损害及食欲下降等。观察组KRS生活质量评分21例明显改善,14例改善,9例稳定,3例降低,获益率为93.61%。对照组有11例明显改善,9例改善,17例稳定,10例降低,获益率为78.72%。结论培美曲塞联合奈达铂治疗晚期肺腺癌效果显著,不良反应小,能明显改善患者的生活质量,安全性较高,值得临床推广和应用。
Objective To investigate the clinical observation of pemetrexed combined with nedaplatin in the treatment of advanced lung adenocarcinoma. Methods 94 patients with advanced lung adenocarcinoma admitted to Xiangcheng People’s Hospital from July 2013 to July 2014 were divided into observation group (47 cases) and control group (47 cases), and the patients in observation group were given training Meitetras combined with nedaplatin treatment, given the control group patients gemcitabine combined with nedaplatin treatment, the two groups were observed treatment effect, adverse reactions, quality of life and other indicators of improvement. Results After treatment, the total effective rate was 91.48% in the observation group and 72.34% in the control group, with significant difference between the two groups (P <0.05). The incidence of leukopenia of grade Ⅲ in the observation group was lower than that of the control group, the difference was statistically significant (P <0.05). However, no significant difference was found in the incidence of other adverse reactions (P> 0.05). Common side effects of chemotherapy were nausea and vomiting, hair loss, bone marrow suppression, liver and kidney dysfunction and loss of appetite. Observation group KRS quality of life score improved significantly in 21 cases, 14 cases improved, 9 cases stable, 3 cases decreased, the benefit rate was 93.61%. The control group, 11 cases improved significantly, 9 cases improved, 17 cases stable, 10 cases reduced, the benefit rate was 78.72%. Conclusion pemetrexed combined with nedaplatin in the treatment of advanced lung adenocarcinoma has significant effect and little adverse reaction, which can significantly improve the quality of life of patients with high safety and is worthy of clinical promotion and application.